COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prospective G7 Dual Mobility Total Hip PMCF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03308929
Recruitment Status : Enrolling by invitation
First Posted : October 13, 2017
Last Update Posted : March 27, 2020
Information provided by (Responsible Party):
Zimmer Biomet

Brief Summary:
This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiographic data.

Condition or disease Intervention/treatment
Clinical Outcomes Functional Outcomes Radiological Outcomes Survivorship Safety Device: G7 Dual Mobility hip

Detailed Description:
This multi-center prospective follow-up study will evaluate clinical outcomes, functional outcomes, radiological outcomes and further characterize the safety profile of the G7 Dual Mobility Hip Arthroplasty System. This will be accomplished by assessing these domains using the Harris Hip Score, UCLA Activity Score, and EQ-5D-3L, obtaining and assessing radiographs and the tracking of device or procedure related adverse events. Subjects will undergo unilateral primary or revision total hip arthroplasty and will then be followed for 10 years with intervals at 6 weeks, 1-, 2-, 3- 5- and 10 years. For the 10 year visit, subjects will not be required to present in their doctor's office, but will fill out a survey. Subsequent to 10 year data collection, the subject's participation in the study will be compete.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Multi-Center Clinical Evaluation Following Total Hip Arthroplasty With the G7 Dual Mobility System
Actual Study Start Date : February 28, 2017
Estimated Primary Completion Date : February 28, 2024
Estimated Study Completion Date : February 28, 2029

Intervention Details:
  • Device: G7 Dual Mobility hip
    Total hip arthroplasty and implantation of the G7 device

Primary Outcome Measures :
  1. Survivorship of the study device [ Time Frame: 5 years ]
    This is assessed by removal of the study device from the patient for any reason, including failure of the device, infection, or traumatic injury.

Secondary Outcome Measures :
  1. Radiographic measurements of the implanted device [ Time Frame: 10 years ]
    Standard AP radiographs of implanted hip will assess the positioning of the device as well as lucencies and other potential anomalies.

  2. Frequency and incidence of adverse events for all subjects with particular focus on those related or potentially related to the device [ Time Frame: 10 years ]
    Assessed by tracking the type of adverse event, severity and relation of the event(s) to the study device

  3. Patient Physical Activity [ Time Frame: 10 years ]
    UCLA activity score - patient self assessment

  4. Patient Quality of Life [ Time Frame: 10 years ]
    EQ-3L-5D quality of life measure - patient self assessment

  5. Harris Hip Score [ Time Frame: 10 years ]
    Harris Hip score measures pain, function, absence of deformity, and range of motion. Scores range from 0-100 with higher scores representing less dysfunction and better outcomes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients undergoing revision hip arthroplasty, undergoing a hip arthroplasty to correct a functional deformity, patients seeking treatment for femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques, and patients with significant hip pain or functional limitations and who are at a high dislocation risk will be considered for the study. Patients may have avascular necrosis, osteo- or rheumatoid arthritis.

Inclusion Criteria:

  • Patients who are undergoing revision hip arthroplasty


  • Patients who are undergoing total hip arthroplasty (THA) for the correction of a functional deformity

    - OR

  • Patients in need of treatment of femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques

    - OR

  • Patients suffer from substantial pain and/or limited function, are appropriate for a primary total hip arthroplasty, considered at high risk for dislocation and have one of the following:

    • Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
    • Rheumatoid arthritis
  • Decision to have a G7 Dual Mobility system implanted was made independently and prior to recruitment into study
  • From 18 to 80 years of age (inclusive) at time of procedure
  • BMI equal to or less than 35
  • Unilateral total hip replacement
  • Willing and able to comply with the study procedures

Exclusion Criteria:

  • Patients undergoing total hip arthroplasty following non-union of previous surgically treated fracture.
  • Infection, sepsis or osteomyelitis at the affected joint
  • Significant osteoporosis as defined by treating surgeon
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption on preoperative radiographs
  • Underwent contralateral THA within 12 months of planned index procedure
  • Contralateral THA planned within 12 months of index procedure
  • Vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease
  • The patient is

    • A prisoner
    • A known alcohol or drug abuser
  • The patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
  • The patient is known to be pregnant
  • The patient has a known sensitivity or allergy to one or more of the implanted materials, inducing but not limited to chromium, cobalt, and ceramic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03308929

Layout table for location information
United States, New Jersey
Jersey City Medical Center
Jersey City, New Jersey, United States, 07302
United States, New Mexico
New Mexico Orthopaedics
Albuquerque, New Mexico, United States, 87106
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Virginia
Tidewater Orthopaedics
Hampton, Virginia, United States, 23666
Ortho Virginia
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
Zimmer Biomet
Layout table for investigator information
Study Director: Kacy Arnold, MS Zimmer Biomet
Layout table for additonal information
Responsible Party: Zimmer Biomet Identifier: NCT03308929    
Other Study ID Numbers: H.CR.I.G.16.5
First Posted: October 13, 2017    Key Record Dates
Last Update Posted: March 27, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes